PixarBio Corporation (PXRB) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
DELISTED
What happened to PixarBio Corporation (PXRB) stock?
PixarBio Corporation (PXRB) no longer trades on public markets. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
PixarBio Corporation (PXRB). PixarBio Corporation is a specialty pharmaceutical company focused on developing neurological drug delivery systems, particularly for post-operative pain management. Their primary focus is on non-opiate pain relief solutions using their NeuroRelease platform. Sector: Consumer cyclical.
Last analyzed: Mar 16, 2026Analyst Coverage for PXRB: PXRB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PXRB against Consumer Cyclical peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
PXRB: this read rests on a single discipline (Legends Council) — the other council disciplines have no scored data yet.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
PixarBio Corporation (PXRB) Consumer Business Overview
PixarBio Corporation, founded in 2014, is a specialty pharmaceutical company developing neurological drug delivery systems, primarily NeuroRelease, for non-opiate post-operative pain management. Operating within the consumer cyclical sector, the company aims to address pain, epilepsy, Parkinson's disease, and spinal cord injuries through innovative drug delivery technologies.
What Is the Investment Thesis for PXRB?
PixarBio Corporation presents a high-risk, high-reward investment opportunity within the specialty pharmaceutical sector. The company's focus on non-opiate pain relief solutions through its NeuroRelease platform addresses a significant market need, given the ongoing opioid crisis and the demand for safer pain management alternatives. However, as an OTC-listed company with a small market capitalization of $0.00B and a beta of -55.70, PixarBio faces substantial challenges related to funding, regulatory approvals, and market adoption. Successful clinical trials and eventual commercialization of NeuroRelease could drive significant value, but the path forward is fraught with uncertainty. Investors should carefully consider the speculative nature of this investment and the potential for significant losses.
Based on FMP financials and quantitative analysis
PXRB Key Highlights
Focus on non-opiate pain relief solutions addresses a critical market need.
- NeuroRelease platform represents a novel approach to neurological drug delivery.
- Pre-clinical development stage presents both high risk and high potential reward.
- OTC listing indicates limited liquidity and higher volatility.
- Market capitalization of $0.00B reflects the company's early stage and speculative nature.
Who Are PXRB's Competitors?
PXRB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| RGS Regis Corporation | $27.40 | -0.72% | $68.5M | 525-pillar |
| MED Medifast, Inc. | $12.05 | -0.74% | $134M | 515-pillar |
| WW WW International, Inc. | $14.90 | +0.85% | $149M | — |
| CSV Carriage Services, Inc. | $32.34 | +0.47% | $513M | 505-pillar |
| BFAM Bright Horizons Family Solutions Inc. | $64.27 | -2.41% | $3.38B | 585-pillar |
| CVSA Covista Inc. | $125.09 | +1.18% | $4.26B | 895-pillar |
| FTDR Frontdoor, Inc. | $79.56 | -1.07% | $5.59B | 905-pillar |
| HRB H&R Block, Inc. | $44.89 | +0.02% | $5.69B | 955-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PXRB's Key Strengths?
Proprietary NeuroRelease platform.
- Focus on non-opiate pain relief.
- Potential to address a significant market need.
- Innovative drug delivery technology.
What Are PXRB's Weaknesses?
Early stage of development.
- Limited financial resources.
- OTC listing indicates higher risk.
- Dependence on successful clinical trials.
What Could Drive PXRB Stock Higher?
Announcement of results from pre-clinical studies of NeuroRelease.
- Pursuit of strategic partnerships with pharmaceutical companies.
- Development of new drug delivery systems.
- Filing of Investigational New Drug (IND) application with the FDA.
- Exploration of expansion into new therapeutic areas.
What Are the Key Risks for PXRB?
Failure to secure funding for ongoing operations.
- Unsuccessful clinical trials for NeuroRelease.
- Regulatory hurdles and delays in obtaining approvals.
- Competition from established pharmaceutical companies.
- Limited liquidity and price volatility due to OTC listing.
What Are the Growth Opportunities for PXRB?
- Successful clinical trials for NeuroRelease: Achieving positive results in clinical trials for NeuroRelease would be a major catalyst for PixarBio, validating its technology and opening the door for regulatory approvals. The market for post-operative pain management is substantial, estimated to be worth billions of dollars annually. Positive trial outcomes could attract partnerships with larger pharmaceutical companies, providing funding and expertise for commercialization. Timeline: Ongoing clinical development with potential for initial results within the next 1-2 years.
- Expansion of NeuroRelease platform to other neurological conditions: PixarBio's NeuroRelease platform has the potential to be adapted for the treatment of other neurological conditions beyond post-operative pain, such as epilepsy, Parkinson's disease, and spinal cord injury. These markets represent significant growth opportunities, with each condition affecting millions of people worldwide. Expanding the platform would require further research and development, but could significantly increase the company's market potential. Timeline: 3-5 years for initial expansion into new indications.
- Strategic partnerships with pharmaceutical companies: Partnering with established pharmaceutical companies would provide PixarBio with access to funding, expertise, and distribution channels needed to commercialize its products. These partnerships could take the form of licensing agreements, joint ventures, or acquisitions. The pharmaceutical industry is actively seeking innovative pain management solutions, making PixarBio an attractive potential partner. Timeline: Ongoing discussions with potential partners, with potential for a deal within the next 1-2 years.
- Securing regulatory approvals for NeuroRelease: Obtaining regulatory approvals from the FDA and other regulatory agencies is essential for commercializing NeuroRelease. The regulatory process is complex and time-consuming, but successful approvals would provide PixarBio with a significant competitive advantage. The company's focus on non-opiate solutions could potentially expedite the approval process, given the FDA's emphasis on addressing the opioid crisis. Timeline: 2-3 years for initial regulatory approvals.
- Development of novel drug delivery systems: PixarBio's expertise in neurological drug delivery systems could be leveraged to develop new and innovative delivery methods for other drugs and biologics. This could involve creating targeted delivery systems that improve drug efficacy and reduce side effects. The market for advanced drug delivery systems is growing rapidly, driven by the increasing demand for personalized medicine. Timeline: Ongoing research and development with potential for new products within the next 3-5 years.
What Are PXRB's Competitive Advantages?
- Proprietary NeuroRelease platform.
- Expertise in neurological drug delivery.
- Focus on non-opiate pain relief.
- Patents protecting their technology.
What Does PXRB Do?
Founded in 2014 and based in Medford, Massachusetts, PixarBio Corporation is a specialty pharmaceutical and biotechnology company dedicated to the pre-clinical and clinical development of neurological drug delivery systems. The company's core focus is on creating innovative solutions for post-operative pain management, with a strong emphasis on non-opiate alternatives. PixarBio researches and develops delivery systems for drugs, devices, and biologics targeted at treating a range of neurological conditions, including pain, epilepsy, Parkinson's disease, and spinal cord injury. Their principal product platform, NeuroRelease, is designed for the therapeutic release of non-opiate drugs, aiming to provide effective post-operative, acute, and chronic pain relief. The company's pre-clinical models are geared towards demonstrating the efficacy and safety of their drug delivery systems. PixarBio's mission is to revolutionize pain management and neurological treatments through advanced drug delivery technologies, offering potential alternatives to traditional opioid-based pain relief methods.
What Products and Services Does PXRB Offer?
- Develop neurological drug delivery systems.
- Focus on pre-clinical and clinical development.
- Target post-operative pain management.
- Research non-opiate pain relief solutions.
- Utilize the NeuroRelease platform.
- Develop treatments for epilepsy and Parkinson's disease.
- Explore solutions for spinal cord injury.
How Does PXRB Make Money?
- Develop and patent neurological drug delivery systems.
- Conduct pre-clinical and clinical trials to validate efficacy and safety.
- Seek regulatory approvals for their products.
- Commercialize products through partnerships or direct sales.
What Industry Does PXRB Operate In?
PixarBio Corporation operates within the consumer cyclical sector, specifically in the personal products and services industry, focusing on the pharmaceutical and biotechnology segment. The market for pain management solutions is substantial, driven by an aging population and increasing prevalence of chronic pain conditions. The industry is characterized by intense competition, with numerous companies developing both opioid and non-opioid pain relief therapies. PixarBio's focus on non-opiate solutions positions it to capitalize on the growing demand for safer alternatives, but it faces competition from established pharmaceutical companies with greater resources and market access.
Who Are PXRB's Key Customers?
- Hospitals and surgical centers.
- Pain management clinics.
- Patients suffering from post-operative pain.
- Pharmaceutical companies seeking innovative drug delivery technologies.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price 5 days old
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 4 snapshots
| 2026-08-23 | 46 |
| 2026-08-24 | 46 |
| 2026-08-25 | 46 |
| 2026-08-26 | 46 |
What changed?
The score has stayed at 46.
Over the same 3 days the stock moved +0.0%.
Company Profile
PixarBio Corporation operates in the Personal Products & Services industry within the Consumer Cyclical sector. The company is led by CEO Francis M. Reynolds. PXRB has traded publicly since 2023.
PXRB Financials
Bull Case vs Bear Case
Bull Case
- Proprietary NeuroRelease platform.
- Focus on non-opiate pain relief.
- Potential to address a significant market need.
- Innovative drug delivery technology.
Bear Case
- Early stage of development.
- Limited financial resources.
- OTC listing indicates higher risk.
- Dependence on successful clinical trials.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PXRB Latest News
No recent news available for PXRB.
Leadership: Francis M. Reynolds
CEO
Francis M. Reynolds is the CEO of PixarBio Corporation, managing a team of 30 employees. He leads the company's strategic direction and oversees the development of its neurological drug delivery systems.
Track Record: Due to limited information, specific achievements and strategic decisions under Francis M. Reynolds' leadership cannot be detailed. The company's progress in pre-clinical development of NeuroRelease is a key focus.
PXRB OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that PixarBio Corporation may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity can be sporadic. Investing in OTC Other stocks carries significant risks due to the potential for fraud, lack of liquidity, and limited regulatory oversight. This tier is substantially different from exchanges like the NYSE or NASDAQ which have rigorous listing standards.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Potential for fraud or manipulation.
- Lack of liquidity.
- Higher price volatility.
- Limited regulatory oversight.
- Verify the company's financial statements.
- Research the background of the management team.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with OTC investing.
- Review the company's filings with the SEC (if any).
- Consult with a financial advisor.
- Check for any regulatory actions or legal disputes.
- Focus on a specific therapeutic area (pain management).
- Development of a proprietary technology platform (NeuroRelease).
- Pre-clinical development activities.
- Company has been in operation since 2014.
- Presence of a CEO and management team.
Common Questions About PXRB (Consumer Cyclical)
What happened to PixarBio Corporation (PXRB) stock?
PixarBio Corporation (PXRB) no longer trades on public markets. The figures below are historical and are not a current quote.
Can I still buy PXRB shares?
No. PXRB stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for PXRB elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before PXRB stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to PixarBio Corporation. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does PixarBio Corporation do?
PixarBio Corporation is a specialty pharmaceutical company focused on developing neurological drug delivery systems, primarily for post-operative pain management. The company's core technology is the NeuroRelease platform, designed to deliver non-opiate drugs for pain relief.
What do analysts say about PXRB stock?
As of March 16, 2026, there is no available analyst coverage or consensus rating for PixarBio Corporation (PXRB). Given its OTC listing and small market capitalization, the company is not widely followed by analysts. Investors should conduct their own thorough research and due diligence before considering an investment in PXRB.
What are the main risks for PXRB?
Investing in PixarBio Corporation (PXRB) carries significant risks, primarily due to its OTC listing, early stage of development, and limited financial resources. Securing funding for ongoing operations is also a major challenge.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available on the company's financials and operations.
- OTC listing indicates higher risk and lower transparency.